Gastroesophageal Junction Cancer Clinical Trials

Find Gastroesophageal Junction Cancer Clinical Trials Near You

Iparomlimab and Tuvonralimab in Combination With Albumin-Bound Paclitaxel, Oxaliplatin, and S-1 as Neoadjuvant Therapy for Locally Advanced Gastric or Gastroesophageal Junction Cancer: A Single-center, Single-arm, Prospective, Open-label, Phase 2 Clinical Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a single-center, single-arm, phase 2 clinical study testing a new neoadjuvant (pre-surgery) treatment for patients with locally advanced gastric cancer or gastroesophageal junction (GEJ) cancer. The treatment combines two parts: (1) a novel bispecific immunotherapy drug, iparomlimab and tuvonralimab (Qibain®) , which helps the immune system attack cancer cells by blocking the PD-1 and CTLA-4 pathways; and (2) a standard chemotherapy regimen called nab-P-SOX, made up of nab-paclitaxel, oxaliplatin, and S-1. About 28 adults (aged 18-75) with previously untreated, HER2-negative, locally advanced gastric or GEJ adenocarcinoma (clinical stage cT3-4aN+M0) will receive this combination before their planned surgery. The main goal is to see how well the tumor shrinks, measured by the objective response rate (RECIST v1.1). Secondary goals include the rate of complete response in the removed tumor tissue (pathological complete response), how often the cancer is removed with clear margins (R0 resection), survival outcomes, and the safety of the treatment. All participants will be closely followed to track both benefits and side effects. The study is sponsored by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, with funding and the study drug provided by Qilu Pharmaceutical Co., Ltd.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Age 18-75 years

• Histologically confirmed gastric or gastroesophageal junction adenocarcinoma, clinical stage cT3-4aN+M0

• Resectable disease, as determined by the surgical investigator

• No prior radiotherapy, chemotherapy, or other systemic antitumor therapy

• HER-2 negative

• ECOG performance status 0-1

• Life expectancy greater than 6 months

• Adequate organ function: hemoglobin \>= 90 g/L; absolute neutrophil count \>= 1.5 x 10\^9/L; platelet count \>= 100 x 10\^9/L; serum creatinine \<= 1.5 x ULN; ALT/AST \<= 2.5 x ULN; total bilirubin \<= 1.5 x ULN; amylase/lipase \< 1.5 x ULN; INR/APTT \<= 1.5 x ULN; urine protein \< 2+; LVEF \>= 50%

• Women of childbearing potential must be non-pregnant, non-lactating, and agree to use adequate contraception

• Provision of written informed consent and anticipated good compliance

Locations
Other Locations
China
Shanghai Jiaotong Univeristy School of Medicine Affiliated Ruijin Hospital
RECRUITING
Shanghai
Contact Information
Primary
Hao Li
lh11001@rjh.com.cn
86-21-64370045
Time Frame
Start Date: 2025-02-01
Estimated Completion Date: 2030-02-01
Participants
Target number of participants: 28
Treatments
Experimental: Iparomlimab and Tuvonralimab Plus nab-P-SOX as Neoadjuvant Therapy
All participants in this single experimental arm receive neoadjuvant therapy with iparomlimab and tuvonralimab (QL1706; trade name Qibain®) in combination with the nab-P-SOX chemotherapy regimen, administered as 4 cycles on a 21-day schedule, followed by curative-intent surgery. On Day 1 of each 21-day cycle:~Iparomlimab and tuvonralimab: 5 mg/kg by intravenous (IV) infusion; Nab-paclitaxel (albumin-bound paclitaxel): 150 mg/m² IV; Oxaliplatin: 130 mg/m² IV; S-1 (tegafur/gimeracil/oteracil): oral, twice daily on Days 1-14, with dose by body-surface area (\<1.25 m²: 40 mg/dose; 1.25-1.5 m²: 50 mg/dose; \>1.5 m²: 60 mg/dose).~Curative-intent surgery is performed within 4 weeks after the last neoadjuvant cycle. Postoperative adjuvant treatment is left to the investigator's discretion. Dose interruptions, reductions, or permanent discontinuation follow the protocol's toxicity management rules (NCI CTCAE v5.0); dose is not re-escalated after reduction.
Sponsors
Leads: Ruijin Hospital
Collaborators: Qilu Pharmaceutical Co., Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials